source
- Merck partners with Sarah Cannon to accelerate community oncology trialsMerck and Sarah Cannon Research Institute announced a collaboration to improve patient access to oncology trials at community sites across the United States. The partnership will use SCRI’s Accele…
- Amylyx reports avexitide cuts severe hypoglycemia by 55% in bariatric surgery patientsAmylyx Pharmaceuticals announced that its GLP-1 blocker avexitide achieved the primary endpoint in a late‑stage trial, reducing serious to severe hypoglycemic events by 55% compared with placebo in…